The funding round was led by Flash Ventures and Global Founders Capital, with participation from Y Combinator and Columbia Lake Partners.
"B2B BNPL players so far have been largely focused on B2B e-commerce where ticket sizes are small and lenders rely on standard credit data to make limited credit decisions. We’re excited to see Tranch making B2B BNPL accessible to more complex lending demands involving larger volumes and longer durations, all of which creates a hugely scalable international market opportunity through their full lending tech stack."
The financing round was co-led by Speedinvest and firstminute capital to help double the startup engineering team.
"In one case, a machine learning engineer used Tenyks to identify the root causes of 80% of their algorithm’s failures. These findings helped them deliver higher quality results to their customers because of the significantly improved system performance. Moreover, future new deployments can be onboarded in half the time because the engineers can now focus their efforts on alleviating the key bottlenecks,"
The UK digital health startup has closed its pre-seed raise with backing from Y Combinator and multiple angel investors.
"It is a huge achievement for us to be accepted onto Y Combinator and we’re incredibly excited to be a part of such a prestigious global movement that has an unparalleled track record for success. I know personally just how debilitating tinnitus can be and so as a team, we’re looking forward to learning from the very best innovators and entrepreneurs as we explore new ways to accelerate our growth and make a difference in the lives of as many people living with tinnitus as possible. Coupled with our pre-seed investment round, 2022 is shaping up to be a truly formidable year for Oto and for the tinnitus community."
Tiger Global leads Series A investment into experience commerce platform Easol.
"It’s been a tough two years, however, very inspiring to watch our incredible team pull together in extreme circumstances to support our creators through the hardest time of their businesses to come out of this stronger than ever."
The London-based biotechnology firm raised the capital from backers including Cantos Ventures and Y Combinator.
"The global pandemic has catapulted RNA therapeutics into the mainstream, yet the field is constrained to targeting the liver. Sixfold’s iterative platform technology and use of machine learning will unlock the power of mRNA and RNAi for many diseases across various tissue types. We are delighted to support the Company in this seed round and look forward to their rapid progress over the coming years."
